LONDON, April 10, 2009--Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, announces the recent publication in The Lancet (11 April 2009, vol 373, pages 1264-1274) of Juvista (avotermin) trial results from three statistically significant, double-blind, placebo-controlled phase I/II studies (1002, 1005 and 0036) for the improvement of skin scarring.
This publication provides detailed data from three statistically significant trials which demonstrate that Juvista (avotermin) treatment results in scars which resemble more closely normal skin, in both appearance and structure, compared to either placebo or standard care treatments.
A commentary on the publication is provided in the same issue of The Lancet by Dr Edward E Tredget, Professor of Plastic Surgery at the University of Alberta, who highlights the promise of this pioneering work for the future treatment of a range of fibrotic disorders.
The studies were conducted by Renovo and Juvista (avotermin) is now in Phase 3 development in Europe, with the first EU trial due to report in the first half of 2011.
Professor Mark WJ Ferguson, CEO of Renovo, commented:
“We are very pleased to see these trial results published in The Lancet. Juvista (avotermin) is a new class of prophylactic medicine that promotes the regeneration of healthy skin and improves scar appearance.
“With low doses injected locally around the time of surgery, Juvista (avotermin) is a generally well tolerated and convenient treatment. These studies demonstrate that Juvista (avotermin) has potential to provide an accelerated and permanent improvement in scarring.”
official website:http://www.renovo.com/content.asp?c_id=9
關於這藥物的機轉：
Juvista, is a therapeutic application of human recombinant Transforming Growth Factor β3 (TGFβ3). TGFβ3 is present at high levels in developing embryonic skin and in embryonic wounds that heal with no scar, but by contrast, is present at low levels in adult wounds that scar.
他們家的藥物還有：
Adaprev (an injectable solution of Mannose 6 Phosphate):Scar reduction in tendons
Prevascar (INN: Ilodecakin) is a therapeutic formulation of human recombinant Interleukin 10 (IL–10):Reduced Scarring
Juvidex is a topical formulation of the sugar Mannose-6-Phosphate (M-6-P)Improved skin appearance
RN1005 targeting the Wnt pathway to reduce scarring and enhance tissue regeneration:for reduction of scarring
都是針對除疤的商品
留言列表
醫藥類 (14)
